Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Commission on Cancer, Chicago, IL; and Wright State University, Dayton, OH.
J Oncol Pract. 2018 Jan;14(1):e59-e72. doi: 10.1200/JOP.2016.020446. Epub 2017 Nov 1.
Survival is considered an important indicator of the quality of cancer care, but the validity of different methodologies to measure comparative survival rates is less well understood. We explored whether the National Cancer Data Base (NCDB) could serve as a source of unadjusted and risk-adjusted cancer survival data and whether these data could be used as quality indicators for individual hospitals or in the aggregate by hospital type.
The NCDB, an aggregate of > 1,500 hospital cancer registries, was queried to analyze unadjusted and risk-adjusted hazards of death for patients with stage III breast cancer (n = 116,787) and stage IIIB or IV non-small-cell lung cancer (n = 252,392). Data were analyzed at the individual hospital level and by hospital type.
At the hospital level, after risk adjustment, few hospitals had comparative risk-adjusted survival rates that were statistically better or worse. By hospital type, National Cancer Institute-designated comprehensive cancer centers had risk-adjusted survival ratios that were statistically significantly better than those of academic cancer centers and community hospitals.
Using the NCDB as the data source, survival rates for patients with stage III breast cancer and stage IIIB or IV non-small-cell lung cancer were statistically better at National Cancer Institute-designated comprehensive cancer centers when compared with other hospital types. Compared with academic hospitals, risk-adjusted survival was lower in community hospitals. At the individual hospital level, after risk adjustment, few hospitals were shown to have statistically better or worse survival, suggesting that, using NCDB data, survival may not be a good metric to determine relative quality of cancer care at this level.
生存被认为是癌症治疗质量的重要指标,但衡量比较生存率的不同方法的有效性则知之甚少。我们探讨了国家癌症数据库(NCDB)是否可以作为未经调整和风险调整的癌症生存数据的来源,以及这些数据是否可以作为单个医院或按医院类型的总体质量指标使用。
NCDB 是由>1500 家医院癌症登记处组成的汇总数据库,用于分析 III 期乳腺癌(n=116787)和 IIIB 或 IV 期非小细胞肺癌(n=252392)患者的未经调整和风险调整的死亡风险。数据在医院水平上进行分析,并按医院类型进行分析。
在医院水平上,经过风险调整后,很少有医院的比较风险调整后的生存率具有统计学上的显著差异。按医院类型,美国国立癌症研究所指定的综合性癌症中心的风险调整后生存率明显高于学术癌症中心和社区医院。
使用 NCDB 作为数据源,与其他医院类型相比,III 期乳腺癌和 IIIB 或 IV 期非小细胞肺癌患者在国立癌症研究所指定的综合性癌症中心的生存率在统计学上更好。与学术医院相比,社区医院的风险调整后生存率较低。在医院水平上,经过风险调整后,很少有医院的生存率具有统计学上的显著差异,这表明,使用 NCDB 数据,生存率可能不是衡量这一水平的癌症治疗相对质量的一个很好的指标。